Noteworthy, Cx43 emerges as a possible target in multiple non-CNS diseases (e.g., vascular diseases, wound healing diseases, retinopathies, cardiac diseases, cancer, and chronic kidney, liver, and lung diseases) and brain diseases (Alzheimer’s disease, epilepsy, and stroke) and several agents that inhibit Cx43 channels are currently investigated as potential clinical therapeutics by various pharma and biotech companies [217]. This evidence concerns the gene GJA1 and brain disorder.